Long-term follow-up after AHB-137 treatment for hepatitis B
Part of Digestive system, Infections clinical trials.
This study follows participants with chronic hepatitis B who previously responded to the drug AHB-137. The goal is to track long-term health and safety after their treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received at least one dose of the study drug AHB-137 in a previous trial.
- You had a complete or partial response to AHB-137 without needing extra medication.
- That response lasted until the end of the previous study.
- You are not currently in another clinical trial.
- You do not have suspected cancer or a condition that requires hospital care during this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This study tests a new injection called AHB-137 in people with chronic hepatitis B who have never received antiviral treatment. The goal is to see if it can help reduce the hepatitis B virus in the body and improve liver health.
This study tests how a new investigational drug called AHB-137 moves through your body and affects safety in people with mild-to-moderate liver problems compared to people with normal liver function. The goal is to understand if the drug works safely in people whose livers don't work as well as they should.
This study tests a new injection called AHB-137 combined with other hepatitis B drugs. It aims to see if the combination can better control the virus in people with chronic hepatitis B who are already on antiviral pills.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This study follows patients who completed a previous trial of peginterferon alfa-2b and tenofovir for chronic hepatitis B. It checks long-term health and offers further treatment options based on your response to the earlier therapy.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.